HDFC Pharma and Healthcare Fund Regular Plan IDCW Payout
HDFC Asset Management Co Ltd
₹20.81 (+0.77%)
NAV as of 9 Oct 2026
Minimum Investment: ₹100
Return
21.84% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.18%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹100
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,197
Invested ₹1,000
▲+19.67%1 year
₹1,218
Invested ₹1,000
▲+21.84%3 years
₹1,278
Invested ₹1,000
▲+27.78%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +21.84% | +27.78% | — | — |
| Cumulative returns (%) | +21.84% | +108.63% | — | — |
Fund Manager
| Manager | Nikhil Mathur |
|---|---|
| Role | Manager |
| Manager Tenure | 2.99 yrs |
About Fund
| Date of Incorporation | 4 Oct 2023 |
|---|---|
| Fund House | HDFC Asset Management Co Ltd |
| Custodian | Hongkong And Shanghai Banking Corp Ltd |
| Registrar / Transfer Agent | HDFC Asset Management Co Ltd |
| Address | 1 Queens Road Central |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Divi's Laboratories Ltd | 9.54% |
| Sun Pharmaceuticals Industries Ltd | 8.94% |
| Glenmark Pharmaceuticals Ltd | 6.06% |
| Torrent Pharmaceuticals Ltd | 4.08% |
| Max Healthcare Institute Ltd Ordinary Shares | 4.06% |
| Lupin Ltd | 4.04% |
| Fortis Healthcare Ltd | 4.02% |
| Laurus Labs Ltd | 4.02% |
| Cipla Ltd | 3.94% |
| Aster DM Quality Care Ltd Ordinary Shares | 3.84% |
| Neuland Laboratories Ltd | 3.70% |
| Alkem Laboratories Ltd | 3.67% |
| Krishna Institute of Medical Sciences Ltd | 3.64% |
| Eris Lifesciences Ltd Registered Shs | 3.55% |
| Ipca Laboratories Ltd | 3.53% |
| Anthem Biosciences Ltd | 3.48% |
| Acutaas Chemicals Ltd | 3.24% |
Investment Strategy
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
To generate long-term capital appreciation
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.